Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Lokon Pharma’s immunostimulatory gene therapy, delivered in oncolytic adenoviruses, are poised to enter pivotal trials for cancer. Biovian Oy is manufacturing Lokon’s immunotherapeutics for these trials and beyond.
By harnessing its proprietary nanotechnology ‘pullulan nanogel’, United Immunity is creating a generation of novel immunotherapies for cancer and infectious diseases such as COVID-19.
The survival rate of liver failure patients may be improved by bioartificial liver which uses human hepatocyte-like cells transdifferentiated from umbilical cord fibroblasts, developed by Chinese company, Hexaell Biotech.
Avalon GloboCare is a global leader in the development of transformative immune effector cell therapies. With 15 autologous and off-the-shelf cell therapy programs for a wide array of hematologic malignancies and solid tumors, Avalon is expanding horizons in cancer immunotherapy and cellular medicine.
By focusing on immunogenic cell death (ICD) as a complementary mechanism to existing cancer immunotherapy strategies, Phosplatin Therapeutics is building a global network of partnerships to help advance the application of its lead ICD inducer, PT-112, against a variety of cancers.
Combining single-cell genomics and bioinformatics, Decibel Therapeutics is developing precision gene therapies to treat disorders affecting the inner ear.
Combining cell sorting technology with artificial intelligence, Japan-based ThinkCyte aims to discover novel high-value therapeutic cells, new functional genes, and novel drug candidates for itself and its partners worldwide.
With unmatched industry expertise, Dark Horse Consulting provides strategic and technical services to help clients realize their goals of bringing therapies to patients and commercialization. Those seeking services from Dark Horse Consulting range from biopharmaceutical companies to tools and tech providers to investment firms.
With vast experience in cell-based therapies, Minaris Regenerative Medicine has become a trusted global partner for clinical and commercial manufacturing of cell therapies.
COVID-19 has accelerated development and awareness of next-generation therapeutics, including mRNA vaccines, boosting the field’s dealmaking and investment activities.
Mustang Bio is developing next-generation CAR T and gene therapies for cancer and rare genetic diseases, with lead clinical programs in non-Hodgkin lymphoma, chronic lymphocytic leukemia, and X-linked severe combined immunodeficiency.
Revitope is developing conditionally activated, T cell–engaging, bispecific antibodies containing dual tumor-specific antigens and split T cell–targeting paratopes that are unique in their high tolerability. The company is now focused on advancing its therapies to deliver safer and more efficacious therapies especially in solid cancer settings.
